Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Draadje OT, bijzaken & geleuter in de marge!

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1.189 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 60 »» | Laatste | Omlaag ↓
  1. [verwijderd] 31 maart 2006 21:57
    Fort Dodge Animal Health Announces Licensure of a Reverse Genetics Avian Influenza Vaccine

    Fort Dodge to Supply French Ministry of Agriculture With Millions of Doses of Vaccine

    OVERLAND PARK, Kan., March 30 /PRNewswire/ -- Fort Dodge Animal Health, a division of Wyeth , today announced the National Agency of Veterinary Medicine (France) has given temporary approval for Poulvac(R) FluFendTM i H5N3 RG, an inactivated virus reverse genetics avian vaccine to aid in the prevention of avian influenza (AI) caused by the H5N1 virus.

    In collaboration with St. Jude Children's Research Hospital and the University of Wisconsin, Fort Dodge developed the vaccine as part of a control and eradication program in response to the growing concern about global avian influenza and the need to protect poultry from the disease.

    Reverse genetics, a cutting-edge technology being utilized in the development of human vaccines, has enabled Fort Dodge to take components from three different influenza viruses and bring them together in a single product. This technology, licensed from the Wisconsin Alumni Research Foundation, not only results in a product that offers safe and effective protection against the most prevalent strain of AI currently threatening France, but also allows for differentiation between a field strain and the vaccine, using diagnostic tests that Differentiate Infected from Vaccinated Animals-the so-called DIVA system. DIVA is often used as part of a monitoring program to demonstrate the flock is not infected with the field virus.

    The reverse genetics technology used for the preparation of the Fort Dodge H5 influenza vaccine was developed by Erich Hoffmann, Ph.D., Division of Virology, St. Jude Children's Research Hospital. This process, known as the eight plasmid reverse genetics system, is a significant advantage for future poultry vaccines because it allows the antigen content to be standardized, according to Robert Webster, Ph.D., holder of the Rose Marie Thomas Chair, Department of Infectious Diseases, at St. Jude. "The standardization of antigen content is similar to human influenza vaccines, and more recently for equine influenza vaccines," Webster said. "Thus, this new vaccine is a major advance for preventing infection of poultry with H5N1."

    The French Ministry of Agriculture and Fisheries has requested an initial supply of 7 million doses of this vaccine for use in ducks as part of an avian influenza control program. Approval was based on the efficacy of the vaccine, which demonstrated the ability to reduce mortality, virus re-isolation and shedding after challenge with highly pathogenic AI viruses. The French Ministry recently started vaccinating outdoor ducks in parts of France, as authorities consider these areas at high risk for the transmission of AI virus by migrating birds.

    As part of AI control programs, various Fort Dodge conventional vaccines have been registered or used in other parts of the world to provide safe and efficacious protection against Avian Influenza. In several different countries, Fort Dodge's products have been supplied as vaccine banks for use in the event of an outbreak. In addition to H5N3 RG, Fort Dodge has approvals for vaccines including H5N9, H5N2, H7N1, H7N2 and H7N3 strains.
    interestalert.com/story/siteia.shtml?...
  2. [verwijderd] 2 april 2006 11:17
    Posted on: 31 Mar 06
    DSM Biologics and AC Immune SA Sign a Memorandum of Understanding

    Parsippany, March 30, 2006 Lausanne, March 30, 2006

    DSM Biologics and AC Immune SA, Lausanne, Switzerland, have signed a Memorandum of Understanding in which the parties have agreed that DSM will be the Development and Manufacturing Partner for AC Immune’s monoclonal antibody against Alzheimer’s disease. The Development and Manufacturing activities will be executed in DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands.

    "After an intensive market analysis we have decided to choose DSM as our partner for the production of AC Immune’s conformation-specific monoclonal Alzheimer’s antibody, ACI-01-Ab7, based on the best quality to cost offerings by DSM" said Andrea Pfeifer, CEO of AC Immune.

    "DSM Biologics is very exited to contribute to the development of AC Immune’s promising drug for treating Alzheimers’s disease and is looking forward to the mutually beneficial collaboration" says Terry Novak, Chief Marketing Officer, DSM Pharmaceutical Products.

    About DSM Biologics
    DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM
    Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics’ FDA-approved facility in Groningen, The Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM’s manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. For more information, please visit www.dsmbiologics.com

    www.pharmiweb.com/PressReleases/press...
  5. [verwijderd] 2 april 2006 18:56
    In afwachting van UMN Pharma/Crucell obesitasmiddel.

    Hospitals Make Changes to Care for Obese By JIM SALTER, Associated Press
    Sat Apr 1, 1:46 PM ET

    ST. LOUIS - Going to the hospital is rarely fun. If you weigh over 300 pounds like Beth Henk, it can be embarrassing. "I've flipped an exam table — I sat on the end of it and it just flipped up," said Henk, whose weight peaked at 745.

    When her son was born three years ago, "I had to sit in the hospital bed the whole time — the hospital's rocker wouldn't fit my butt."
    Today Henk helps Barnes-Jewish Hospital in St. Louis find better ways to deal with the growing number of very obese patients, an issue for many U.S. hospitals. Barnes-Jewish is replacing beds and wheelchairs with bigger models, widening doorways, buying larger CT scan machines, even replacing slippers and gowns.

    Last year, patient care director Colleen Becker decided to check the numbers. She looked at a daily hospital census — about one-third of the 900 patients weighed 350 pounds or more.
    Startled, Becker checked another date, then another. The numbers were consistent. On some days, half the patients were obese. Some weighed 500 pounds or more.
    "We ran the data again to make sure we weren't hallucinating," Becker said. "We weren't. So we had to somehow figure out the appropriate supplies, equipment, training and care for the patients we're dealing with."

    The answer was a "bariatric care team," which Henk serves on, to address the challenges posed by obese patients. Those challenges are many.
    Hospitals around the nation are working with equipment suppliers to accommodate larger patients, said Elizabeth Lietz, a spokeswoman for the American Hospital Association. And it's not just for the patients.

    ATF Healthcare, a union representing 70,000 nurses and other workers at hospitals in 18 states, last week called for new laws forcing hospitals to buy equipment such as portable hoists to prevent worker injuries.
    A union-commissioned survey of more than 900 nurses and X-ray technicians found the majority have chronic pain or have suffered injuries from lifting and moving patients.

    At Barnes-Jewish, lift machines help some patients get in and out of bed. Chairs have been made stronger and wider. Lights have been added at floor level because the bodies of extremely obese people can cast a shadow that makes it hard to see the floor.
    The hospital is replacing many of its beds — built to handle people weighing up to 350 pounds — with beds for 500-pound patients.

    "Three-hundred-fifty pounds is nowhere near what we need for beds now," said Art Kidrow, a nurse manager at Barnes-Jewish. "We've had some 650-pounders up here."
    Some wings of Barnes-Jewish are replacing 36-inch-wide doorways with those that are 48 or 52 inches wide. The bathrooms are being fitted with floor-mounted commodes that can't be pulled out of the wall, and rooms reconfigured so patients can essentially get out of bed and step into the bathroom.
    Gowns are bigger. Wheelchairs are wider. Even hospital-issued slippers come in extra-large sizes because the standard-issued footies were cutting off circulation for some patients.

    Issues extend beyond the patient's room. Operating tables have been widened because the girth of some patients was lapping over the table, in some cases all the way to the floor, Becker said. CT scan machines weren't wide enough. Syringes with the longest available needles — 4 1/2 inches — couldn't penetrate the fat.

    Along with doctors and nurses, the hospital's 30-member bariatric care team includes former patients like Henk and people from the hospital's engineering and housekeeping units.

    Henk, 41, represents both patients and those who try to help the obese — she is program manager for Washington University's weight management program.
    She's been heavy for as long as she can remember — she was in Weight Watchers by age 5. "Everybody in my family is at least 100 pounds overweight," she said.
    Gastric bypass surgery seven years ago helped her shed some weight, but she's dropped to 315 pounds mostly through better eating and exercise.
    Still, she knows what larger people go through at the hospital.
    "I believe in dignity for whomever you are," Henk said. "It can be scary, too. If people are trying to lift you up and somebody doesn't have the strength, it's very scary."

    Based on recommendations from the team, Barnes-Jewish has developed a protocol for lifting heavy patients.
    The hospital is also working with suppliers. Manufacturers now offer more than 1,000 items specifically for obese patients, said Sandy Wise, of Novation LLC, a Texas-based company that provides contracting services between hospitals and manufacturers.
    "It's been a trend probably for the last four or five years," Wise said. "Hospitals are continuing to see an increase in obese patients, and it affects every department. You have to think of the patient from head to toe, everything they do in the hospital until they walk out the door or they die."

    In fact, Barnes-Jewish is striving to make even the end more dignified. Becker said the law requires a leak-proof body bag. Some patients were so large they wouldn't fit in them. The hospital is working with a vendor to develop a wider bag.

    news.yahoo.com/s/ap/20060401/ap_on_he...
    _ylt=Am6fbwmedGj1zN3xbqCbfUCs0NUE;_ylu=X3oDMTA3czJjNGZoBHNlYwM3NTE-
  6. [verwijderd] 3 april 2006 09:46
    DSM Venturing makes follow-on investment in personalized nutrition company Sciona

    Heerlen (NL),Boulder (USA),3-Apr-2006 08:15 CET


    DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a follow-on financing round of 6.5 million USD in the personalized nutrition company Sciona. Herewith DSM has become a major shareholder in Sciona.

    Personalized nutrition is nutrition based on individual dietary recommendations derived from knowledge of the individual’s lifestyle, nutritional status and/or genetic makeup. It is aimed at promoting health, well-being, performance and potentially reducing the risk of health problems. DSM has decided to focus on personalized nutrition as one of its key innovation areas because it optimally combines DSM’s strengths in nutrition, food and biotechnology with the demands of a more health conscious and aging population.

    Rob van Leen, Chief Innovation Officer at DSM: ‘We are very pleased with our increased shareholding in Sciona because relations like these will help us to accelerate our activities in the emerging business area of personalized nutrition. We will further increase our interaction with Sciona via a supervisory board representative and joint development projects.’

    DSM Venturing

    DSM Venturing is an active investor in several Venture Capital Funds and start-up companies in the field of Nutrition, Pharma and Performance Materials. DSM Venturing's mission is to explore emerging markets and technologies in order to enhance DSM's product portfolio and create value. For more information about DSM Venturing see www.dsm-venturing.com.

    Sciona Inc.

    Sciona is a privately held, international company that provides personalized health and nutrition recommendations based on an individual's diet, lifestyle and unique genetic profile. The Company has created a powerful set of tools that enables consumers to harness the scientific information uncovered in the Human Genome Project. Sciona is headquartered in Boulder, Colorado with offices in Europe, and research facilities on the Yale University campus. For more information about Sciona see www.sciona.com.

    For more information:
    DSM Corporate Communications
    tel. +31 (45) 5782035
    media.relations@dsm.com

    DSM Investor Relations
    tel. +31 (45) 5782864
    investor.relations@dsm.com
    www.dsm.com/en_US/html/media/press_re...
  7. [verwijderd] 3 april 2006 10:04
    BioInvent and Immusol to Collaborate on Antibody Therapeutic for Macular Degeneration
    Monday April 3, 2:00 am ET

    SAN DIEGO & LUND, Sweden--(BUSINESS WIRE)--April 3, 2006--BioInvent International AB (SAX:BINV) and Immusol, Inc. announced today a collaboration for the development of a fully human n-CoDeR® antibody for the treatment of age-related macular degeneration (AMD) and other ophthalmic disorders. Macular degeneration, a poorly treated condition, is the most common cause of vision loss in people over 60, affecting 20-25 million people worldwide. It is characterised by abnormal and uncontrolled vessel growth in the eye.

    The collaboration will bring together a rich portfolio of expertise in the area of therapeutic antibody research and development. Immusol will contribute its expertise in ophthalmology and intellectual property rights covering the use of antagonists against a biological target identified to play an important role in the underlying pathological process of AMD. BioInvent will contribute its knowledge and experience in angiogenesis, immunology and therapeutic antibody discovery and development. Under the terms of the collaboration, the parties will share costs and revenues in further development and commercialization.

    Commenting on the collaboration, Svein Mathisen, President and CEO of BioInvent, said, "We are very pleased to add this project to our growing portfolio and to work with Immusol's expertise in ophthalmic disorders. We believe that this project if successfully developed could potentially offer significant clinical benefit to a patient population poorly treated today."

    Dr. Flossie Wong-Staal, Chief Scientific Officer and Executive Vice President of Research and Development of Immusol, said, "We are happy to work with BioInvent to leverage BioInvent's antibody expertise in an important disease area. By developing antibodies against a non-VEGF target with proven preclinical efficacy, we hope to tackle wet AMD from a different angle."
    biz.yahoo.com/bw/060403/2006040200500...
  8. [verwijderd] 3 april 2006 10:13
    Dr. Flossie ......(!!!!!!!!!!!!!!!!!!!!)........grappig Floszje!!

    quote:

    flosz schreef:

    BioInvent and Immusol to Collaborate on Antibody Therapeutic for Macular Degeneration
    Monday April 3, 2:00 am ET

    SAN DIEGO & LUND, Sweden--(BUSINESS WIRE)--April 3, 2006--BioInvent International AB (SAX:BINV) and Immusol, Inc. announced today a collaboration for the development of a fully human n-CoDeR® antibody for the ............

    Dr. Flossie ......(!!!!!!!!!!!!!!!!!!!!)........Wong-Staal, Chief Scientific Officer and Executive Vice President of Research and Development of Immusol,...........

    said, "We are happy to work with BioInvent to leverage BioInvent's antibody expertise in an important disease area. By developing antibodies against a non-VEGF target with proven preclinical efficacy, we hope to tackle wet AMD from a different angle."
    biz.yahoo.com/bw/060403/2006040200500...
  9. [verwijderd] 3 april 2006 10:24
    Press Release

    Preclinical Study Supports Therapeutic Potential of Micromet's Novel BiTET
    Candidate MT110 Against Solid Tumors

    April 03, 2006 - Munich, Germany - Micromet reports preclinical data on
    MT110, a novel candidate in the Company's pipeline of proprietary BiTET
    molecules. MT110 targets the Ep-CAM antigen, which is frequently
    overexpressed on most human carcinomas including breast, prostate, colon,
    lung, stomach, pancreas, head & neck and ovary cancer.

    The study published in the recent issue of Molecular Immunology (2006;
    43:1129-1143) (1) demonstrates that MT110 could efficiently redirect
    unstimulated human T cells to lyse cancer cells from all tumor cell lines
    tested. The BiTET candidate was also highly efficacious in a NOD/SCID
    mouse model with subcutaneously growing human colon cancer cells. Five
    daily doses of 1 microgram of MT110 were sufficient to completely inhibit
    tumor outgrowth or eradicate established tumors in all mice treated. In
    addition, MT110 could eliminate patient-derived metastatic ovarian cancer
    tissue growing in mice. In all experiments, MT110 was capable of
    effectively and specifically activating human T cells against tumor cells
    without any additional costimulation of T cells. Of note, T cell
    activation by MT110 was only triggered in the presence of target cells.

    "Our new results reiterate the unique properties already seen with other
    candidates of the BiTET family," Patrick Baeuerle, CSO of Micromet,
    pointed out. "It is however remarkable that MT110 was able to eradicate
    patient-derived tumor tissue implanted in immune-deficient mice, by
    redirecting just those few human T cells carried along in the patient
    sample. These tumor-resident T cells are thought to be anergic. Their
    activation by BiTET molecules could provide a truly novel therapeutic
    modality with strong potential for the treatment of late stage tumors that
    are in high need for more treatment options."

    MT103, the most advanced candidate of the BiTET family is currently in
    clinical phase I for the treatment of Non-Hodgkin's Lymphoma.

    In January 2006, Micromet announced a definitive agreement to merge with
    CancerVax Corporation (NASDAQ: CNVX) to create a transatlantic,
    NASDAQ-listed company with a highly differentiated drug development
    pipeline focused on oncology, autoimmune and inflammatory diseases, and a
    proprietary technology base for the development of antibody-based product
    candidates. The merger is subject to a number of conditions and is
    expected to close in the second quarter of 2006. Upon closing of the
    transaction, the Company's shares are expected to continue to trade on the
    NASDAQ National Market. Upon completion of the merger, CancerVax will be
    renamed "Micromet, Inc.", and application will be made to NASDAQ to change
    the ticker symbol to "MITI". On March 31, 2006, CancerVax filed an amended
    registration statement on Form S-4 with the U.S. Securities and Exchange
    Commission in connection with the transaction. This registration statement
    contains a proxy statement/prospectus.
  10. [verwijderd] 3 april 2006 15:05
    Dit is tenminste nog eens een deal.

    GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease
    LONDON, PHILADELPHIA and SAN FRANCISCO, April 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- GlaxoSmithKline (NYSE: GSK) and Sirna Therapeutics, Inc. (Nasdaq: RNAI) today announced that they are forming an exclusive multi-year strategic alliance focused on discovery, development and commercialisation of novel RNA interference (RNAi)-based therapeutics for respiratory diseases. The alliance combines Sirna's extensive expertise in short interfering RNA (siRNA) chemistry and biology with GSK's industry leading capabilities in the development and commercialisation of novel therapies for respiratory diseases.

    Sirna will receive an initial payment of $12 million, made up as cash and purchase of Sirna common stock, priced at $ 8.36 per share. Under the agreement, Sirna may also receive milestone payments in excess of $700 million for collaboration and clinical development events, as well as royalties on worldwide sales of products which successfully result from the alliance. In addition, Sirna will be eligible to receive contract manufacturing revenues.

    "By combining GSK's pulmonary drug delivery expertise with Sirna's advanced application of RNAi technology, this alliance will expedite the development of novel therapeutics with potential use in a number of respiratory diseases such as asthma and COPD," said Dr. Garth Rapeport, Senior Vice President, Respiratory & Inflammation CEDD, at GSK. "We recognise Sirna's leadership in the area of RNAi-based therapeutics and hope for the potential benefits this research will bring to patients."

    Under the terms of the agreement, Sirna will provide GSK optimised and formulated siRNAs against Sirna and GSK targets. GSK will assume all responsibility for the further preclinical and clinical development of these compounds as well as worldwide commercialisation of products resulting from the alliance.

    "This collaboration is an extraordinary opportunity for us to work with GSK, the world's second largest pharmaceutical company, to develop important new medicines to treat patients with serious respiratory diseases," stated Howard W. Robin, President and CEO of Sirna Therapeutics. "With this collaboration, Sirna continues to successfully execute our strategy to ally selected therapeutic programs or drug targets with pharmaceutical companies that lead the industry in their respective markets."

    Sirna will conduct a live audio webcast conference call to discuss this alliance on April 3, 2006 at 8:30 am ET. To participate over the Internet, go to www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. To access the live telephonic broadcast, domestic callers should dial (877) 502-9272; international callers may dial (913) 981-5581.

    An audio webcast replay will be available on Sirna's web site, www.sirna.com, for 30 days. Additionally, a telephonic replay of the call will be maintained through midnight, Monday, April 17, 2006. To access the replay, please dial (888) 203-1112 from the U.S. or (719) 457-0820 when calling internationally, using confirmation code 8943556.

  11. [verwijderd] 3 april 2006 15:24
    De koers van Sirna was afgelopen vrijdag al me 10% gestegen (ZONDER nieuws).
    En staat nu voorbeurs +16% hoger n.a.v. de deal met GSK.

    Dit onderschrijft mijn theorie dat je de koers van Crucell op zult zien lopen, nog VOORDAT er een officieel PB (STAR, Malaria) naar buiten zal zijn gebracht.
    Grote deals houdt je nu eenmaal niet binnenskamers!
    Tip: doe hier je voordeel mee.......

    Grtz,
    ZEKER
  13. [verwijderd] 3 april 2006 16:32
    Nu Crucell kopen of vasthouden wat je al hebt.
    Zodra de stijging inzet, je aandelen verkopen en omzetten in call opties (call opies kopen)!

    Deze call opties weer verkopen zodra de boel stabiliseert (op de dag van het PB) en je aandelen Crucell dezelfde of de volgende dag weer terugkopen (long positie aandelen weer op hold).

    Snap ie? ;-))

    Grtz,
    ZEKER
  14. forum rang 10 voda 3 april 2006 17:21
    quote:

    zeker schreef:

    Nu Crucell kopen of vasthouden wat je al hebt.
    Zodra de stijging inzet, je aandelen verkopen en omzetten in call opties (call opies kopen)!

    Deze call opties weer verkopen zodra de boel stabiliseert (op de dag van het PB) en je aandelen Crucell dezelfde of de volgende dag weer terugkopen (long positie aandelen weer op hold).

    Snap ie? ;-))

    Grtz,
    ZEKER
    Alleen iemand met een MBA opleiding kan zoiets bedenken:)

    Voda
  15. [verwijderd] 3 april 2006 19:25
    biz.yahoo.com/bw/060403/2006040300602...

    quote:

    schreef:

    Chiron Announces Amended Merger Agreement with Novartis
    Monday April 3, 12:22 pm ET
    Novartis to Acquire All Outstanding Chiron Shares for $48.00 Per Share in Cash

    EMERYVILLE, Calif.--(BUSINESS WIRE)--April 3, 2006--Chiron Corporation (Nasdaq:CHIR - News) today announced that it has entered into an amendment to its previously announced merger agreement with Novartis providing for Novartis to increase to $48.00 per Chiron share the price it will pay for the approximately 56 percent of Chiron shares that Novartis does not already own. The amended merger agreement has been unanimously approved by Chiron's non-Novartis directors.

    ADVERTISEMENT
    The merger will now require a majority of outstanding shares as of the record date to be voted in favor of the transaction. Both CAM North America and ValueAct Capital have informed Chiron and Novartis that they and their affiliated entities intend to vote in favor of the transaction, subject to the fiduciary and legal obligations applicable to them.

    Chiron today also announced that it has reached an agreement in principle to settle all claims in the previously reported stockholder actions challenging the proposed transaction with Novartis. The proposed settlement is subject to court approval following notice to the class and a hearing.

    Chiron will promptly send updated proxy materials to shareholders and plans to convene the special shareholders meeting as scheduled on April 12, 2006, and to immediately adjourn the meeting and then reconvene on April 19, 2006. As all necessary regulatory approvals were previously received, Chiron expects the merger to close promptly after the stockholder vote on April 19, 2006.

    About Chiron

    Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com.
  16. [verwijderd] 3 april 2006 21:34
    PATH launches new vaccine development effort to prevent pneumonia, save a million children a year

    Grant from the Bill & Melinda Gates Foundation to accelerate development of pneumococcal vaccines for developing countries

    Seattle, April 3, 2006—PATH today announced a new program aimed at preventing pneumonia, a major childhood illness that causes the deaths of up to one million children every year—primarily in developing countries. The program will seek a vaccine that is capable of addressing a broad range of strains of pneumococcus, a bacterium that causes pneumonia. PATH, an international nonprofit organization with more than 27 years of global health experience, will work with public- and private-sector partners to identify and test promising pneumococcal vaccines. The five-year effort is supported by a US$75 million grant from the Bill & Melinda Gates Foundation.

    PATH’s pneumococcal vaccine effort builds on work begun in 2005 to produce protein-derived vaccines to prevent strains of pneumococcus not addressed by existing vaccines. The approach is aimed at identifying proteins that are common to most strains of pneumococcus, then systematically testing these in the lab. The hypothesis is that a new vaccine or combination of vaccines containing “common proteins” could protect against the majority of types of pneumococcus. A vaccine that can confer broad immunity holds the potential to deliver the most effective protection to children worldwide.

    John Boslego, MD, will lead PATH’s pneumococcal vaccine development. Boslego joined PATH in February 2006 after leading vaccine development at Merck and Co., Inc. Boslego said, “We hope this new effort will encourage as many scientists and manufacturers as possible to advance their research toward preventing this childhood disease. Pneumonia is a familiar household word, and the world can do a lot to prevent childhood deaths, especially in developing countries, by coming up with solutions to prevent it.” He added, “We are hoping to shorten the timeline for getting these vaccines to the areas in greatest need.”

    Regina Rabinovich, MD, MPH, director of infectious diseases for the Gates Foundation, said, “Pneumococcal disease is a major global health problem, killing or disabling up to 40 percent of the children who contract it in the developing world.” She added, “Innovation and collaboration are key to developing effective pneumococcal vaccines for global health, and we’re pleased to support PATH in this critical effort.”

    Other partners active in this field include the Pneumococcal Accelerated Development and Introduction Plan (PneumoADIP), based at Johns Hopkins University, a program of the Global Alliance for Vaccines and Immunization (GAVI), and other public-sector partners, vaccine manufacturers, and academic and research institutions.

    The PATH program will be centered on upstream activities; for example, working from discovery to preclinical testing to clinical trials, with an expectation that new and promising vaccines will reach the developing world in the shortest amount of time possible.

    The timing of this announcement coincides with a major meeting of scientists, pharmaceutical representatives, and other leading experts on pneumococcal disease that is taking place in Alice Springs, Australia. World experts meeting there are sharing their knowledge and research findings about the global epidemiology and burden of pneumococcal disease, and identifying tools to prevent and control the disease. Experts plan to announce a call for “Development of a Global Action Plan Against Pneumonia” on April 6, 2006.
    www.path.org/news/pr-040306-pneumonia...
  18. [verwijderd] 3 april 2006 23:11
    Biotech Turns in Mixed Performance in Q1 06
    Monday April 3, 11:08 am ET

    SAN FRANCISCO, April 3 /CNW/ -- On the eve of the industry's showcase event BIO 2006, biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. Although the Burrill Mid-Cap Biotech Index dropped almost 5% in March, it still closed out the quarter up 24.5%. Topping this was the Burrill Small-Cap Biotech Index, which was up 2.5% in March and an impressive 26.6% for the first quarter of 2006. This was in stark contrast to the Burrill Biotech Select Index, which was down 4.5% for the month and 0.5% for the quarter. The NASDAQ finished March up 2.5% and a healthy 6% for quarter, and the Dow was also up 1% for month and 3.6% for the quarter...........
    biz.yahoo.com/cnw/060403/ca_burrill_q...
    *******************
    Bio 2006 (incl.Crucell)
    Chicago Annual International Convention
    April 9th - 12 th 2006

    BIO 2006 Set to be Biggest Ever

    www.www.bio.org/events/2006/exhibitor...
  19. [verwijderd] 4 april 2006 07:42
    Persbericht IsoTis - toestemming FDA voor Accell, OrthoBlast
    Publicatiedatum: 04/04/2006 [07:31]

    AMSTERDAM (FD.nl/Betten) - Hier volgt een persbericht uitgegeven door IsoTis:

    IsoTis OrthoBiologics Receives FDA 510(k) Clearances for Accell

    Connexus(TM) and OrthoBlast(R) II in Dental Indications

    LAUSANNE, Switzerland, IRVINE, CA, USA April 4, 2006 - IsoTis S.A.

    (SWX/Euronext: ISON) (TSX: ISO) today announced it received 510(k)

    clearances from the US Food and Drug Administration (FDA) for the use of

    Accell Connexus(TM) and OrthoBlast II(R) in dental indications.

    Pieter Wolters, President and CEO of IsoTis OrthoBiologics said: We are

    very pleased with our ability to now offer a complete product range for

    bone graft substitution in dental indications in the United States. Earlier

    we had obtained FDA 510(k) clearance for DynaGraft II (TM) and OsSatura BCP

    (TM) in dental indications. While our focus as a company will remain on

    spinal and orthopaedic indications, our differentiated portfolio of

    products for dental indications should enable us to benefit from

    opportunities in the dental field as well.

    Accell Connexus is a highly osteoinductive bone graft substitute that

    provides exceptional handling and graft containment. It is part of the

    Companys proprietary Accell(R) technology product line. Accell Connexus is

    a putty with an array of growth factors, including TGF- â1 and various

    natural human bone morphogenetic proteins (nhBMPs). Compared to 1st

    generation DBM products, the AccellRx process on which Accell Connexus is

    based yields a higher level of TGF- Beta-1 and nhBMPs, including BMP-2,

    BMP-4 and BMP-7, which act synergistically to stimulate new bone formation.

    Employing a state-of-the-art reverse phase medium (RPM), Accell Connexus

    thickens at body temperature and resists irrigation so the nhBMPs are

    delivered at the surgical site where they are needed.

    OrthoBlast II is a combination of demineralized bone matrix particles (DBM)

    with cancellous bone chips delivered in RPM. Therefore, the products it is

    malleable at operating room temperatures, but thickens when placed in the

    operative site. This allows the DBM particles and bone chips to be

    contained at the graft site with minimal loss through irrigation and

    suction.

    IsoTis OrthoBiologics, the operating subsidiary of IsoTis S.A., has a

    product portfolio with several innovative and proprietary natural and

    synthetic bone graft substitutes on the market and others in development,

    an established North American independent distribution network, and an

    expanding international presence. The companys main commercial operations

    are based out of Irvine, CA; its international sales headquarters is based

    in Lausanne, Switzerland.

    (c) Het Financieele Dagblad in samenwerking met Betten Beursmedia News (contact: webred@fd.nl/ 020-5928456)

  20. [verwijderd] 4 april 2006 08:30
    Genentech finds high drug prices stick to teflon image
    San Francisco Business Times - March 31, 2006by Daniel S. Levine

    During Genentech's annual investor meeting in March in New York, CEO Art Levinson made an unusual pitch to analysts and investors.

    He touted the fact that EBay, Adobe and Microsoft all boast bigger profit margins than Genentech.

    Though it's not the typical point you'd expect a CEO to make to Wall Street, Levinson was not trying to convince the audience that there were more attractive investments for them. Instead, he was trying to assure the room that Genentech was not gouging cancer patients.

    "For anyone out there to think we have these outrageous profits and we are profiteering on the backs of patients," he said, "I would really like to sit down with anybody and have that dialogue -- and I'd be prepared to do that as long as it takes."

    Genentech may still remain the Bay Area's biotech darling -- an engine of innovation, life-saving therapies and new-company creation.

    But for some, Genentech is no different than its big pharmaceutical brethren. After all, it's one thing to bullseye womp rats in your T-16 back home, but if you grow up to become a Jedi Master, you'll be seen as nothing more than the son of the guy who roams the galaxy reducing planets to cosmic dust.

    The controversy Genentech faces over the pricing of its drugs should remind the rest of the biotechnology industry how fragile the goodwill it enjoys is, and how it changes once a company moves from the lab to the marketplace.

    Levinson's remarks came in response to several stories, most notably a front-page article in The New York Times in February that focused on expectations that Genentech would price Avastin for breast and lung cancer at $100,000 a dose.

    That article was followed in March with a story on the high cost of cancer drugs and the fact that prices bear little relation to their cost of development and production. The story focused on a tenfold increase in the price for nitrogen mustard, a cancer drug marketed as Mustargen, after Ovation Pharmaceuticals bought the rights to it from Merck. But it also pointed to the example of Avastin, which it said Genentech planned to double the price of, when it wins approval for use in breast and lung cancer patients.

    There was, however, a detail left out. Aside from the fact that Levinson insists Genentech has not yet made a pricing decision, dosing for breast and lung cancer patients will be twice the amount used for colorectal patients. As the Times later noted in a correction, the higher price related to the fact that more drug would be needed for those disease and not because Genentech planned to increase the price per dose.
    www.bizjournals.com/sanfrancisco/stor...
1.189 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 60 »» | Laatste |Omhoog ↑

Direct naar Forum

Indices

AEX 882,27 -0,04%
EUR/USD 1,0717 +0,21%
FTSE 100 8.147,03 +0,09%
Germany40^ 18.128,90 +0,06%
Gold spot 2.334,21 -0,07%
NY-Nasdaq Composite 15.983,08 +0,35%

Stijgers

Philip...
+29,35%
Alfen ...
+14,76%
EBUSCO...
+6,88%
FASTNED
+4,79%
EXOR NV
+3,96%

Dalers

Vastned
-6,87%
VIVORY...
-5,88%
ASMI
-4,39%
ADYEN NV
-2,42%
BESI
-2,42%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!